Wockhardt Share Price Surge 18% after US FDA Accepts NDA for New Antibiotic Zaynich

December 01, 2025: Wockhardt Limited (NSE WOCKPHARMA | BSE: 532300) announced that the US FDA has formally accepted its New Drug Application (NDA) for Zaynich. The shares of the company reacted positively to the announcement as they rose by over 18%.

Key Details

The company made a regulatory filing announcing that the United States Food and Drug Administration (US FDA) has accepted its NDA for Zaynich. The application was first filed on September 30, 2025. The company also clarified that the US FDA has assigned the application a priority review. This is because Zaynich has great potential in being able to address urgent and unmet medical needs. 

Significance of the Acceptance

This acceptance is significant because Zaynich is a New Chemical Entity (NCE). The acceptance of its NDA marks the first time that an Indian pharmaceutical company has filed and received US FDA approval for an NCE-based NDA. This will significantly boost the presence not only of Wockhardt but also of Indian pharmaceutical companies in the industry.

Zaynich

Zaynich is an antibiotic which is used to treat complicated urinary tract infections (cUTIs), which are caused by Multi Drug Resistant (MDR) gram-negative bacteria. It has shown potent activity against the bacteria. This means that it has the potential to resolve urgent and unmet medical needs, as the MDR gram-negative bacteria cause prolonged hospitalizations and significant mortality worldwide.

Development of Zaynich

As per Wockhardt, the development of Zaynich started back in 2011. So far, the company has steered non-clinical, clinical and regulatory pathway for it. The company states that Zaynich’s NDA acceptance by the US FDA has encouraged it to further its efforts in developing advanced anti-infective solutions.

Stock Performance

The share price of Wockhardt Limited was trading at ₹1,466.20 as of December 01, 2025, 14:19 pm. This was an 18.72% or ₹231.20 rise from its previous close of ₹1,235.00. The intraday range has been between ₹988.00 and ₹1,482.00. The company has had an active trading session so far. Its total market capitalization stands at ₹23,821.35 crore. Further, it had total traded value and volume of ₹1,464.80 crore and 103.78 lakh shares, respectively.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations